Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasma Exchange | 4 | 2019 | 23 | 1.760 |
Why?
|
| Hypocalcemia | 5 | 2019 | 19 | 1.510 |
Why?
|
| Calcium Gluconate | 2 | 2019 | 6 | 1.230 |
Why?
|
| Calcium | 5 | 2019 | 573 | 0.840 |
Why?
|
| Blood Component Removal | 2 | 2019 | 16 | 0.660 |
Why?
|
| Renal Dialysis | 1 | 2016 | 198 | 0.450 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 1999 | 8 | 0.400 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 1999 | 73 | 0.390 |
Why?
|
| Babesia microti | 1 | 2009 | 7 | 0.320 |
Why?
|
| Babesiosis | 1 | 2009 | 12 | 0.320 |
Why?
|
| Transfusion Reaction | 1 | 2009 | 46 | 0.310 |
Why?
|
| Erythrocytes | 1 | 2009 | 149 | 0.300 |
Why?
|
| Infusions, Intravenous | 2 | 2019 | 174 | 0.300 |
Why?
|
| Premedication | 2 | 2018 | 20 | 0.290 |
Why?
|
| Acquired Hyperostosis Syndrome | 1 | 2025 | 2 | 0.250 |
Why?
|
| Osteomyelitis | 1 | 2025 | 25 | 0.240 |
Why?
|
| Gene Expression | 4 | 1999 | 839 | 0.240 |
Why?
|
| Rheumatic Diseases | 1 | 2025 | 40 | 0.230 |
Why?
|
| Erythrocyte Transfusion | 2 | 2018 | 74 | 0.230 |
Why?
|
| Endometrium | 2 | 1999 | 30 | 0.190 |
Why?
|
| Citric Acid | 2 | 2018 | 20 | 0.180 |
Why?
|
| Plateletpheresis | 2 | 2017 | 6 | 0.170 |
Why?
|
| Blood Donors | 2 | 2017 | 23 | 0.170 |
Why?
|
| Catheters, Indwelling | 1 | 2019 | 69 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2019 | 121 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 87 | 0.150 |
Why?
|
| RNA, Messenger | 5 | 1999 | 1539 | 0.150 |
Why?
|
| Quality of Life | 1 | 2025 | 1226 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 63 | 0.140 |
Why?
|
| Fallopian Tubes | 2 | 1994 | 11 | 0.140 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2017 | 10 | 0.140 |
Why?
|
| Citrates | 1 | 2017 | 17 | 0.140 |
Why?
|
| Humans | 18 | 2025 | 63299 | 0.140 |
Why?
|
| Cathepsin D | 2 | 1996 | 11 | 0.140 |
Why?
|
| Cholecalciferol | 1 | 2017 | 28 | 0.130 |
Why?
|
| RNA, Neoplasm | 2 | 1996 | 34 | 0.130 |
Why?
|
| In Situ Hybridization | 5 | 1999 | 216 | 0.130 |
Why?
|
| Serum Albumin, Human | 1 | 2016 | 7 | 0.130 |
Why?
|
| Leukapheresis | 1 | 2016 | 11 | 0.130 |
Why?
|
| Middle Aged | 5 | 2025 | 17555 | 0.130 |
Why?
|
| Glucose | 1 | 2018 | 467 | 0.120 |
Why?
|
| Ovary | 1 | 1995 | 100 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 285 | 0.110 |
Why?
|
| Female | 12 | 2025 | 32793 | 0.110 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1993 | 98 | 0.110 |
Why?
|
| Mannosephosphates | 1 | 1993 | 2 | 0.100 |
Why?
|
| Receptor, IGF Type 2 | 1 | 1993 | 3 | 0.100 |
Why?
|
| Delaware | 2 | 2011 | 8 | 0.100 |
Why?
|
| Anemia, Neonatal | 1 | 2011 | 3 | 0.090 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2011 | 18 | 0.090 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2011 | 38 | 0.090 |
Why?
|
| Infant, Premature, Diseases | 1 | 2011 | 47 | 0.090 |
Why?
|
| Hepatitis, Chronic | 1 | 1990 | 6 | 0.090 |
Why?
|
| Hepatitis B | 1 | 1990 | 32 | 0.080 |
Why?
|
| RNA | 1 | 1993 | 423 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 124 | 0.080 |
Why?
|
| DNA, Viral | 1 | 1990 | 232 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2019 | 5657 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 1199 | 0.070 |
Why?
|
| Male | 5 | 2025 | 29823 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 972 | 0.070 |
Why?
|
| Factor XI | 1 | 2005 | 2 | 0.060 |
Why?
|
| Factor IX | 1 | 2005 | 7 | 0.060 |
Why?
|
| Plasminogen | 1 | 2005 | 8 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2025 | 3285 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 1995 | 517 | 0.060 |
Why?
|
| RNA-Directed DNA Polymerase | 2 | 1995 | 37 | 0.060 |
Why?
|
| Peptide Hydrolases | 1 | 2005 | 77 | 0.060 |
Why?
|
| Adult | 4 | 2025 | 16784 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 1995 | 893 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2025 | 753 | 0.050 |
Why?
|
| Registries | 1 | 2025 | 888 | 0.050 |
Why?
|
| Iron Overload | 1 | 2018 | 4 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 7 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 4 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 2 | 1994 | 34 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2017 | 8 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2674 | 0.030 |
Why?
|
| Citrus | 1 | 2017 | 42 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 228 | 0.030 |
Why?
|
| Breast Diseases | 2 | 1996 | 39 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 232 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2017 | 102 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1996 | 21 | 0.030 |
Why?
|
| Theca Cells | 1 | 1995 | 1 | 0.030 |
Why?
|
| Luteal Cells | 1 | 1995 | 2 | 0.030 |
Why?
|
| Granulosa Cells | 1 | 1995 | 16 | 0.030 |
Why?
|
| Pregnancy, Ectopic | 1 | 1995 | 10 | 0.030 |
Why?
|
| Luteal Phase | 1 | 1995 | 28 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 234 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 1994 | 28 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1994 | 15 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1994 | 47 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1121 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 735 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 1994 | 114 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1994 | 172 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1996 | 429 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 342 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 1993 | 128 | 0.020 |
Why?
|
| Pregnancy | 2 | 1995 | 2330 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1995 | 863 | 0.020 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1990 | 6 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1990 | 18 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 147 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 1990 | 15 | 0.020 |
Why?
|
| Menopause | 1 | 1993 | 258 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 189 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2011 | 81 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3762 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 768 | 0.020 |
Why?
|
| Virus Replication | 1 | 1990 | 319 | 0.020 |
Why?
|
| DNA Replication | 1 | 1990 | 235 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 1355 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7828 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 2005 | 83 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 2570 | 0.010 |
Why?
|
| Longevity | 1 | 2005 | 113 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 2571 | 0.010 |
Why?
|
| Aged | 1 | 1999 | 14396 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 5343 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 2107 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 953 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6631 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 1146 | 0.010 |
Why?
|
| Cryoultramicrotomy | 1 | 1996 | 1 | 0.010 |
Why?
|
| Matrix Metalloproteinase 11 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 1996 | 7 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1996 | 131 | 0.010 |
Why?
|
| Isomerism | 1 | 1994 | 28 | 0.010 |
Why?
|
| Thymidine | 1 | 1994 | 25 | 0.010 |
Why?
|
| Autoradiography | 1 | 1994 | 53 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1994 | 67 | 0.010 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 1994 | 29 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1994 | 233 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1994 | 134 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1994 | 175 | 0.010 |
Why?
|
| Cell Division | 1 | 1994 | 449 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1994 | 148 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1994 | 141 | 0.010 |
Why?
|
| Mice | 1 | 2005 | 10827 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1994 | 2152 | 0.010 |
Why?
|
| Proteins | 1 | 1994 | 751 | 0.000 |
Why?
|
| Animals | 1 | 2005 | 20634 | 0.000 |
Why?
|